LIXT (Lixte Biotechnology, Inc.) Company Cash on Hand

Graphic logo of lixte.com (LIXT)

Lixte Biotechnology (LIXT) minimizes costs through patent licensing, ensuring a steady stream of free cash flow. The cash balance demonstrates the issuer's liquidity, with the metric holding at 0.00. The development of phosphatase inhibitors creates a foundation for future monetization, although the value of chemical compound protection at early stages remains uncertain.

LIXT - Lixte Biotechnology Holdings Inc. Company Cash Balance over the range 07/04/2022 - 07/06/2026

Financial and market metric breakdowns for Lixte Biotechnology Holdings, Inc. (LIXT)

- current price and projected stock value:
Comprehensive company analysis:LIXT Lixte Biotechnology Holdings
Signature product of lixte.com

This indicator measures actual balance sheet liquidity, uncovering hidden reporting manipulations and cash gap risks through an analysis of cash flow dynamics. By assessing the volume of cash resources, an investor can confirm the ability of Lixte Biotechnology (LIXT) to fund the development of the unique LB-100 drug, whose high market value is driven by the company's exceptional pricing power in the oncology segment.